INTRODUCTION
IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disease characterized by a significant elevation of serum IgG4 concentration and marked infiltration of IgG4-positive plasma cells in an affected organ or affected organs such as lacrimal glands, salivary glands, lymph nodes, pancreas, retroperitoneum, and lungs [1] . A dense lymphoplasmacytic infiltrate and the formation of ectopic lymphoid structures (ELSs) are characteristic histopathological findings in an IgG4-RD lesion [ Figure 1 ]. These findings strongly suggest the preferential involvement of T and B lymphocytes in the development of this disease. Since the establishment of this disease entity, a number of studies have been performed for clarifying the immunological mechanisms of this disease. T cells and their subsets were focused on in the early period of IgG4-RD research. T helper 2 (Th2) cells [2] [3] [4] [5] [6] [7] and regulatory T (Treg) cells [2, 4, [7] [8] [9] [10] were considered as candidates of a main player in IgG4-RD. After such studies on CD4 þ T cells, T follicular helper (Tfh) cells [11,12 & 20] . In this review, we summarize the roles of CD4 þ T-cell subsets and discuss the possible interplay between Tfh cells and Tph cells in the pathogenesis of IgG4-RD.
Th2 CELLS AND ALLERGIES
Patients with IgG4-RD often have allergic disorders such as bronchial asthma and allergic rhinitis [21] . Indeed, levels of Th2 cells and Th2 cytokines including interleukin (IL)-4, IL-5, and IL-10 are frequently increased in affected tissues or peripheral blood of patients with IgG4-RD [2] [3] [4] [5] 7] . Of note, Culver et al. reported associations of IgG4-RD with allergy, atopy, eosinophilia, increased serum levels of IgE, and IgE-positive mast cells in lymphoid and affected tissues. They concluded that levels of IgE could be used for diagnosis and predicting relapse [6] . Taken together, the results suggest that Th2 cells and IgEmediated allergic response play a role in the pathogenesis of IgG4-RD.
However, several recent studies have shown controversial results. Mattoo et al. reported that circulating memory Th2 cells in IgG4-RD are detected in a limited population of subjects with atopy [22] . They also showed that CD4 In order to develop a new drug for IgG4-RD, studies using an animal model of this disease that can provide answers to all of the questions regarding immunological mechanisms are needed. mechanism of IgG4-DS (M. Yamamoto, R. Kamekura, unpublished data). Therefore, it is still not clear how classic Th2 cells and IgE-mediated allergy are involved in the pathogenesis of IgG4-RD.
Treg CELLS
Histopathologically, infiltration of IgG4-positive plasma cells accompanied by storiform fibrosis is usually observed in affected tissues of IgG4-RD [1, 23] . It is well known that IL-10 and TGF-b are key cytokines for IgG4 class-switching and fibrosis, respectively [24] [25] [26] . Therefore, regulatory T (Treg) cells have been focused on from the early period of IgG4-RD research as a pathognomonic source of IL-10 and TGF-b. Indeed, several studies have shown an increased number of Treg cells and increased expression level of their master regulator, Foxp3, in both affected sites and circulating leukocytes in patients with IgG4-RD [2, 4, [7] [8] [9] [10] . We also found increased levels of Treg cells in blood and affected tissues of patients with IgG4-RD (F. Ito, R. Kamekura, unpublished data). Taken together, the results of these studies suggest that Treg cells are preferentially involved in IgG4 class-switching and fibrosis in lesions of IgG4-RD; however, no direct evidence regarding the function of Treg cells in IgG4-RD was shown in those reports. Further studies are probably required to clarify IgG4 class-switching and fibrosis caused by Treg cells in IgG4-RD.
CD4
R CYTOTOXIC T LYMPHOCYTES
cells with a cytotoxic function (named CD4
þ CTLs) have been observed in various immunological conditions such as virus infection, autoimmune diseases, and cancer [27, 28] . CD4 þ CTLs are characterized by their unique function of secreting perforin, granzyme, and IFN-g for killing target cells in an MHC class II-restricted fashion [27, 28] . Recently, there has been an accumulation of experimental evidence suggesting the involvement of CD4 þ CTLs in IgG4-RD. Mattoo et al. first reported the clonal expansion of CD4 þ CTLs in inflamed tissue sites of IgG4-RD. These cells presented SLAMF7, granzyme A (GZMA), IL-1b, and TGF-b, suggesting their capacity related to tissue inflammation and fibrosis. Interestingly, clinical remission induced by rituximab-mediated B-cell depletion seems to be associated with a reduction in CD4 
CD20
-CD27 þ CD38 þ cells) in patients with IgG4-RD [29] . These findings indicate that CD4
þ CTLs collaborate with activated plasmablasts and play an important role in the pathogenesis of IgG4-RD. However, there has been no functional experiment on CD4
þ CTLs in IgG4-RD because of the minor population in CD4 þ T-cell subsets and the lack of specific surface markers for live cell sorting. Additional studies are required in the future to obtain direct evidence of cytotoxicity and fibrosis in affected tissues of IgG4-RD by these cells.
Tfh CELLS
As mentioned above, abundant infiltration of IgG4-positive plasma cells is usually observed in tissue lesions of IgG4-RD [1] . This suggests that dysregulation of the IgG4 class-switch underlies the pathogenesis of IgG4-RD. Tfh cells, which are postulated as a specialized class of effector helper CD4 þ T cells, assist B cells to form germinal centers of lymphoid follicles, and Tfh cells thereby contribute to the class switch recombination of B cells and the selection of high-affinity B cells in germinal centers [30, 31] . Importantly, Tfh cells have the capacity to secrete IL-4 and IL-10, which are key cytokines for IgG4 class-switching [24] . Tfh cells have been considered as a potential key player in the development of IgG4-RD.
It is well known that Tfh cells not only localize in lymphoid tissues but also exist in blood circulation and lesional sites of extra-lymphoid tissues [ 
Tfr CELLS

Tfr cells have recently been characterized as a unique CD4
þ T-cell subset that participates in the control of germinal center formation and class switch recombination of B cells in collaboration with Tfh cells [35] [36] [37] . Tfr cells express CXCR5, which is also shared by B cells and Tfh cells. 
CXCR5
À cells, thus collectively named Tph-like cells here) were significantly increased within CD4 þ T cells in patients with IgG4-RD compared to those in healthy volunteers. We also found that their percentage was positively correlated with serum levels of IgG4 and soluble IL-2 receptor and with the number of involved organs in IgG4-RD patients. In addition, we found that such Tph-like cells frequently expressed GZMA, which is related to a cytotoxic property. Clinical remission achieved by treatment with glucocorticoids clearly led to a numerical reduction of Tph-like cells [19 && ]. Taken together, our findings strongly suggest that circulating Tph-like cells play a pivotal role in the pathogenesis of IgG4-RD.
COLLABORATION OF Tph CELLS AND Tfh CELLS IN THE FORMATION OF ECTOPIC LYMPHOID STRUCTURES
In peripheral tissues of chronic inflammation such as IgG4-RD and RA, aggregations of T cells and B cells (so-called ectopic lymphoid structures, ELSs) frequently develop [46] [ Figure 1 ]. In ELSs, T cell-B cell interactions result in uncontrolled somatic hypermutation, class switch recombination, and differentiation of plasma cells [46] , the functional interplay of which accelerates the development of the disease. progressed remarkably. The appearance of Tph cells and Tfh cells as key players in the pathogenesis of IgG4-RD is one example of the progress in research. Accumulating evidence may lead to the development of specific therapeutic targets and a new strategy for IgG4-RD treatment. Treatment with glucocorticoids is still effective for IgG4-RD; however, it often causes side effects and relapse frequently occurs after tapering or discontinuing administration of glucocorticoids [48] . A new strategy needs to be developed to overcome the problem of relapse and refractory cases of IgG4-RD. Thus, it is important to consider experimental findings and knowledge regarding the pathogenesis of IgG4-RD from direct examination of inflamed tissues from patients with IgG4-RD. Because of the limited availability of clinical specimens, studies using lesional tissues and blood from patients with IgG4-RD are not always straightforward. Evidence obtained from animal models of this disease may also help to address the questions regarding immunological mechanisms.
